IBI-363 is a PD-1/IL-2 bispecific antibody with the functions of blocking the PD-1/PD-L1 pathway and activating the IL-2 pathway. The IL-2 arm of IBI-363 retains affinity for IL-2Ralpha while attenuating its binding capacity to IL-2Rbeta and IL-2Rgamma for toxicity reduction. The PD-1-binding arm of IBI-363 enables PD-1 blockade and the selective delivery of IL-2. IBI-363 can be used for cancer research, such as non-small cell lung cancer[1].
Molecular Weight:
(112.48 kDa)
Purity:
99.60
Target:
Interleukin Related,PD-1/PD-L1
Application Notes:
MCE Product type: Inhibitory Antibodies
* VAT and and shipping costs not included. Errors and price changes excepted
